Ivosidenib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted ivosidenib, while DMC (Denmark), NYE METODER (Norway) and TLV (Sweden) did not recommend it.
The record spans 3.3 years, opening at AWMSG (Wales) on 24 Mar 2023 and running to 2 Jul 2026.
CIPM (Spain) changed its position: not recommended on 20 Nov 2024, recommended by 26 Mar 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 21 of 21 records date from 2023 or later.
7 distinct indication wordings are recorded for ivosidenib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 21 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess ivosidenib, on 24 Mar 2023; HIRA (South Korea) did not open a file until 2 Jul 2026 — a wide spread of 3.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 10 of 21 dated records fall in 2024 alone.
9 of the 12 agencies here assessed ivosidenib more than once, NYE METODER (Norway) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
ivosidenib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for ivosidenib reads 8 recommended, 8 not recommended, 3 restricted and 2 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 25 May 2025 | I kombinasjon med azacitidin til behandling voksne med nylig diagnostisert akutt myelogen leukemi (AML) med en isocitrat… | not introduced | source |
| CHUIKYO (Japan) | 21 May 2025 | ティブソボ錠２５０ｍｇ | listed on the NHI price list · 55 days after PMDA approval | source |
| TLV (Sweden) | 27 Mar 2025 | Tibsovo ingår inte i högkostnadsskyddet | rejection or exclusion | source |
| CIPM (Spain) | 26 Mar 2025 | Indicaciones terapéuticas autorizadas: En combinación con azacitidina, para el tratamiento de pacientes adultos con leuc… | financed by the SNS, on appeal · art. 92 d | source |
| DMC (Denmark) | 29 Jan 2025 | Monoterapi til behandling af lokalt fremskreden eller metastatisk kolangiokarcinom med IDH1 R132-mutation, som tidligere… | Ikke anbefalet | source |
16 further decisions for ivosidenib, across 10 agencies, are not shown here. They include the most recent record on file, 2 Jul 2026 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 14 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 21 decisions for ivosidenib from 12 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.